Printer Friendly

Hackensack Meridian Health administers 1,000th patient with COVID-19 investigative treatments.

M2 PHARMA-May 27, 2020-Hackensack Meridian Health administers 1,000th patient with COVID-19 investigative treatments

(C)2020 M2 COMMUNICATIONS

Hackensack Meridian Health, a comprehensive health network, has administered 1,000 patients with the latest investigative treatments for COVID-19 over the course of the pandemic, it was reported on Tuesday.

The trials have included antiviral drugs to immunotherapies and the potential treatment properties of antibodies in the blood of COVID-19 survivors. The patients have been treated over the course of 10 clinical trials and through compassionate use and expanded use access. The trial include treatments from major pharmaceutical companies and investigator-initiated research.

Robert C Garrett, FACHE, chief executive officer of Hackensack Meridian Health, said, 'We are proud of the dynamic research and clinical impact we are achieving in our health network. Our physicians and scientists are propelling us as we continue to be a progressive leader of positive change amid this pandemic.'

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2020 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 27, 2020
Words:161
Previous Article:US FDA grants approval to Astellas Pharma's VESIcare LS.
Next Article:US FDA grants Investigational New Drug Application approval to Expression Therapeutics' ET3.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters